Jason R. Manro

2.5k citations

28 papers · 1.3k indexed · h-index 14

Oncology top 5%
Molecular Biology
Pharmacology top 1%
Pediatrics, Perinatology and Child Health top 5%
Immunology

Co-authors: Ronald N. Hines Jeffrey Stevens Sevasti B. Koukouritaki Chungang Gu Matthew J. Zaya Peter J. Tandler D. Gail McCarver Allan E. Rettie
Topics: Cancer Immunotherapy and Biomarkers (5 papers)Advanced Breast Cancer Therapies (4 papers)Cancer Mechanisms and Therapy (4 papers)
Cited by: Pharmacology Oncology Pediatrics, Perinatology and Child Health
Journals: PLoS ONE Cancer Research Oncogene
Partner nations: United States Belgium Spain

In The Last Decade

Jason R. Manro

28 papers receiving 1.3k citations

Peers

Countries citing papers authored by Jason R. Manro

Since Specialization

Citations

This map shows the geographic impact of Jason R. Manro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason R. Manro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason R. Manro more than expected).

Fields of papers citing papers by Jason R. Manro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason R. Manro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason R. Manro. The network helps show where Jason R. Manro may publish in the future.

Co-authorship network of co-authors of Jason R. Manro

This figure shows the co-authorship network connecting the top 25 collaborators of Jason R. Manro. A scholar is included among the top collaborators of Jason R. Manro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason R. Manro. Jason R. Manro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	41P Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model 2023 ·ESMO Open ·(unknown),Cecilia Mur,W K Shen,Carlos Marugán,Andrew Capen,L. Julie Huber,Mark Castanares,David Garcia-Tapia,Brian Mattioni,John F. Bastian,Jason R. Manro,(unknown),Michele Dowless,(unknown),Marı́a José Lallena,Alfonso de Dios,(unknown)	1
2	Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models 2022 ·PLoS ONE ·Yanxia Li,Nelusha Amaladas,(unknown),Jason R. Manro,Ivan Inigo,Qi Li,Erik Rasmussen,Manisha Brahmachary,Thompson N. Doman,Gerald E. Hall,Michael Kalos,Ruslan D. Novosiadly,Óscar Puig,Bronislaw Pytowski,David Schaer	11
3	Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies 2021 ·Journal for ImmunoTherapy of Cancer ·Mathilde Poussin,Arlene Sereno,Xiufeng Wu,Flora Huang,Jason R. Manro,Shanshan Cao,Carmine Carpenito,Andrew L. Glasebrook,Daniel J. Powell,Stephen J. Demarest	21
4	Abstract 5225: Temporal inhibition of ERK is sufficient for tumor growth inhibition in KRAS-mutant or BRAF-mutant tumors 2020 ·Cancer Research ·Shripad V. Bhagwat,Weihua Shen,Baohui Zhao,Shufen Cai,(unknown),William T. McMillen,Eunice Yuen,Denis McCann,Jason R. Manro,(unknown),Melinda D. Willard,(unknown),Sheng-Bin Peng	2
5	Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition 2019 ·Molecular Cancer Therapeutics ·Anthony S. Fischl,Xiaoen Wang,Beverly L. Falcón,(unknown),Diane Bodenmiller,Glenn F. Evans,Julie Stewart,(unknown),Philip A. Hipskind,Jason R. Manro,Mark Uhlik,Sudhakar Chintharlapalli,Damien Gerald,David C. Alsop,Laura E. Benjamin,Rupal S. Bhatt	16
6	Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade 2018 ·Journal for ImmunoTherapy of Cancer ·Rikke Holmgaard,David Schaer,Yanxia Li,Stephen Castaneda,Mary Y. Murphy,Xiaohong Xu,Ivan Inigo,(unknown),Jason R. Manro,Philip W. Iversen,David Surguladze,Gerald E. Hall,Ruslan D. Novosiadly,Karim A. Benhadji,Gregory D. Plowman,Michael Kalos,Kyla Driscoll	267
7	Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms 2018 ·Cancer Research ·Ruslan D. Novosiadly,David Schaer,Nelusha Amaladas,Erik Rasmussen,(unknown),(unknown),Carmine Carpenito,Yanxia Li,Shuang Luo,Andrew Capen,Catalina M. Meyer,Xiaodong Huang,Jason R. Manro,Gregory P. Donoho,Thompson N. Doman,Gerald E. Hall,Sandaruwan Geeganage,Michael Kalos	8
8	MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping 2017 ·Investigational New Drugs ·S. Betty Yan,Suzane L. Um,Victoria L. Peek,Jennifer R. Stephens,Wei Zeng,Bruce W. Konicek,Ling Liu,Jason R. Manro,Volker Wacheck,Richard A. Walgren	33
9	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1 2017 ·Oncogene ·S-H Chen,(unknown),(unknown),Robert D. Van Horn,Taiqi Yin,L. Julie Huber,T. Burke,Jason R. Manro,Philip W. Iversen,Wenjuan Wu,Shripad V. Bhagwat,Richard P. Beckmann,Ramón V. Tiu,Sean G. Buchanan,(unknown)	58
10	Abstract 317: Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC) 2017 ·Cancer Research ·Wenjuan Wu,Shripad V. Bhagwat,Constance King,Susan E. Pratt,Xueqian Gong,Julie Stewart,(unknown),(unknown),(unknown),Beverly L. Falcón,Jason R. Manro,William T. McMillen,Ramón V. Tiu,Sheng-Bin Peng,Christoph Reinhard,(unknown),Sean G. Buchanan	1
11	Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade 2017 ·Cancer Research ·Jack Dempsey,Lysiane Huber,Amélie Forest,Jennifer R. Stephens,Thompson N. Doman,Jason R. Manro,Andrew Capen,(unknown),Gregory P. Donoho,Sean G. Buchanan,Alfonso de Dios,Kyla Driscoll,Michael Kalos,Ruslan D. Novosiadly,Richard P. Beckmann,David Schaer	2
12	Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3 2015 ·PLoS ONE ·Jennifer M. Atkinson,Kenneth B. Rank,Yi Arial Zeng,Andrew Capen,Vipin Yadav,Jason R. Manro,Thomas A. Engler,Márcio F. Chedid	91
13	Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models 2014 ·Cancer Research ·S. Betty Yan,Suzane L. Um,Victoria L. Peek,Megan N. Thobe,Kelly M. Credille,Jennifer R. Stephens,Jason R. Manro,Darryl Ballard,(unknown),Joel D. Cook,Bruce W. Konicek,Jeremy R. Graff,Timothy R. Holzer,Richard A. Walgren	1
14	Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET 2013 ·Clinical Cancer Research ·Wenjuan Wu,Bi Chen,Kelly M. Credille,Jason R. Manro,Victoria L. Peek,Gregory P. Donoho,Lei Yan,John A. Wijsman,S. Betty Yan,Richard A. Walgren	53
15	Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein 2013 ·Drug Metabolism and Disposition ·J. William Higgins,Jing Bao,Alice Ke,Jason R. Manro,John K. Fallon,Philip C. Smith,Maciej J. Zamek‐Gliszczynski	75
16	Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer. 2013 ·Cancer Research ·Mark H. Bender,Hong Gao,Andrew Capen,(unknown),Philip A. Hipskind,Jon K. Reel,Maciej J. Zamek‐Gliszczynski,Jason R. Manro,Karim A. Benhadji,Bharvin K.R. Patel	13
17	In Vivo Assay Guidelines 2012 ·Europe PMC (PubMed Central) ·Joseph V. Haas,Jason R. Manro,Harlan E. Shannon,(unknown),(unknown),Arunava Chakravartty,M.G. Chambers,Jianbin Du,Brian J. Eastwood,(unknown),Stephen J. Iturria,Philip W. Iversen,D. Brooke Johnson,Kirk W. Johnson,Michael F. O‘Neill,Hui-Rong Qian,Dana K. Sindelar,Kjell Svensson	1
18	Pharmacological Characterization of cGMP Regulation by the Biarylpropylsulfonamide Class of Positive, Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors 2006 ·Journal of Pharmacology and Experimental Therapeutics ·John Ryder,Julie F. Falcone,Jason R. Manro,Kjell Svensson,Kalpana Merchant	11
19	Developmental Expression of Human Hepatic CYP2C9 and CYP2C19 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Sevasti B. Koukouritaki,Jason R. Manro,(unknown),Jeffrey Stevens,Allan E. Rettie,D. Gail McCarver,Ronald N. Hines	236
20	Developmental Expression of the Major Human Hepatic CYP3A Enzymes 2003 ·Journal of Pharmacology and Experimental Therapeutics ·Jeffrey Stevens,Ronald N. Hines,Chungang Gu,Sevasti B. Koukouritaki,Jason R. Manro,Peter J. Tandler,Matthew J. Zaya	289

About Jason R. Manro

Jason R. Manro is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine, having authored 28 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Mechanisms and Therapy (4 papers). The work is most often cited by research in Pharmacology (323 citations), Oncology (556 citations) and Pediatrics, Perinatology and Child Health (244 citations). Jason R. Manro has collaborated with scholars based in United States, Belgium and Spain. Frequent co-authors include Ronald N. Hines, Jeffrey Stevens, Sevasti B. Koukouritaki, Chungang Gu, Matthew J. Zaya, Peter J. Tandler, D. Gail McCarver, Allan E. Rettie, Philip W. Iversen and Gerald E. Hall. Their work appears in journals such as PLoS ONE, Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact